- Pembrolizumab has the potential to cause fetal harm.

- Animal studies have shown increased severity in certain types of infections, including M.Â tuberculosis, lymphocytic choriomeningitis virus, and hepatitis B virus.

- Pembrolizumab has not been the subject of testing for potential carcinogenicity or genotoxicity.

- Pembrolizumab has an elimination terminal half-life of 27 days.